Peptide bioavailability: why your peptide is a needle, not a pill

Insulin is a peptide. Millions of people inject it every day, and not one of them takes it as a pill. There’s a reason for that. It’s the same reason nearly every peptide in the longevity and recovery world arrives as a vial and a needle instead of a capsule.

Here’s the part worth getting excited about. Once you understand why the needle exists, you can pick up almost any peptide product and answer the single most important question about it before you spend a penny: can this even work? Not whether it’s proven in a trial. Whether the thing in the bottle can get into your body intact and reach the place it’s supposed to act. That’s bioavailability. It’s the most useful word in this entire field, and almost nobody explains it in plain language. So let’s fix that — because it hands you a lens that most people buying peptides simply don’t have.

What bioavailable actually means for you

A peptide is a short chain of amino acids. Think of it as a message — a signal your body already knows how to read. It only does something if enough of the message survives the trip from the bottle to the cells that read it, still in working shape.

Bioavailability is just that survival rate. How much of the dose actually arrives, intact, where it’s meant to go. A peptide can have the most exciting biology in the world and still do nothing for you if the answer is almost none of it got there. Get this one idea and half the confusion around peptides falls away.

Why the gut is the problem — and why the needle solves it

Your gut is a protein shredder. That is its entire job.

The stomach hits swallowed protein with acid and an enzyme called pepsin. The small intestine follows up with trypsin and chymotrypsin, which snip protein chains apart. Then the gut wall is built to wave through single amino acids, not intact chains. A peptide capsule walks into all of that and gets treated like a bite of chicken — taken apart for parts. For most unprotected peptides, the fraction that makes it into your bloodstream in one piece is tiny. Often it rounds to zero.

Your body eats the message before it can be read.

So the needle isn’t a hardcore flex or a marketing gimmick. It’s the delivery engineering that gets the signal past the shredder intact. The vial is a needle because, for most of these molecules, the needle is what makes them work at all. That’s not a flaw in peptides. It’s the reason the route you choose is the whole game — and the reason the legitimate versions are built around solving it.

Three routes, and what each one buys you

For the peptides that show up in longevity and recovery, three routes do the work. Each one is really a different answer to the same question: how do I get the message in without destroying it?

Injection under the skin — a small shot into the fat just below the surface — is the default. It skips the gut entirely, then releases the peptide slowly and fairly predictably into your blood. Insulin works this way. So do the GLP-1 drugs like semaglutide, and most growth-hormone-axis peptides. Nearly all the good human evidence for these was built on injection. It’s the plainest, most reliable way to get a fragile signal where it needs to go.

Nasal spray is the underrated one. The lining of your nose has a rich blood supply and, in places, an almost-direct road to the brain along the smell and facial nerves. For a peptide meant to act on the brain, a spray can deliver the signal there without flooding your whole body first. This is why the Russian neuropeptide tradition leans on it. Selank and semax are dosed as nasal sprays for exactly that reason, and a small tweak to their backbone — a Pro-Gly-Pro tail — keeps them alive long enough for the spray to matter, stretching their working window from minutes to hours.

The pill is the route everyone wants and most peptides can’t survive. The exceptions are peptides engineered to shrug off the gut — built into rings, or made from unusual building blocks the enzymes don’t recognise. Oral semaglutide is the famous one that pulled it off. Most performance and recovery peptides simply aren’t built that way, which is why the capsule versions are the ones to look at hardest.

The one lens that protects you

Here’s where the payoff lands. When you look at any peptide product, ask one question: does the route it’s sold under match the route the evidence was built on?

Sometimes it lines up cleanly. Sometimes the mismatch is the tell.

Take BPC-157, sold as both a capsule and an injection. The animal work behind it was done by injection or by delivering a controlled dose straight into a rat’s stomach — never by a person swallowing a capsule off a shelf. The 2025 literature and patent review by Józwiak and colleagues surveys that animal evidence, and the human pharmacokinetic record is essentially absent from it. No published study measures how much of an oral BPC-157 dose actually survives your gut. The only human exposure on record is a two-person, three-day intravenous pilot — no adverse effects, no biomarker changes, no efficacy endpoint, in a low-impact journal. So the oral capsule is a reasonable bet. It is not a proven one.

GHK-Cu makes the same point from the skin side. The creams are everywhere, and the honest question — does the peptide even cross your skin at a dose that does anything — still doesn’t have a clean answer. We get into that in the GHK-Cu deep-dive.

Selank and semax show the third version. Some Western sellers ship them as nasal sprays, matching the Russian clinical evidence — the 2008 selank anxiolytic study and Gusev’s 1997 semax stroke trial were both intranasal, and the 1999 Russian authorisation of semax is for that specific route. Others ship the same peptides as injectable powder. The brain effects that are the entire point may not survive a route that skips the nose-to-brain shortcut.

Same molecule. Different route. Different question.

The honest boundary

Here’s the clarity, because the lens cuts both ways.

For most of these peptides, the human pharmacokinetic data — the actual measurement of how much gets in and how long it lasts — is thin to absent. Mendias and Awan (2026, Sports Medicine) put the whole class outside FDA-recognised drug frameworks, with scarce controlled data and essentially no human PK on the books. That doesn’t mean these peptides don’t work. It means the route question is often still genuinely open — and now you’re the kind of buyer who knows to ask it.

Where the regulators sit

The route question is one the regulators are starting to look at too. BPC-157 is on the FDA Pharmacy Compounding Advisory Committee’s July 23, 2026 docket for ulcerative colitis, and semax is on the July 24 session for cerebral ischemia, migraine, and trigeminal neuralgia. Selank isn’t on either wave. Whether that review ends up saying anything route-specific — this form yes, that form not yet — is one of the open questions the committee’s work will start to answer. What a PCAC review actually decides is a longer story, told in what a PCAC review actually is.

What the good version looks like

The potential in these peptides is real. The thing standing between the biology and a result you can trust is often just this: getting the right molecule into your body by the right route, at a dose someone actually measured.

Wolverine Health is being built for the version where that isn’t guesswork. A physician who reads the molecule’s file and the route-of-administration file before signing anything. A US-licensed pharmacy compounding against an indication and a route the FDA has genuinely reviewed. An assay on every batch, so the dose on the label is the dose in the vial — delivered the way it’s supposed to be delivered. Leave your email and we’ll tell you the day that version opens.